OptimizeRx (NASDAQ:OPRX) Given New $5.00 Price Target at Barclays

OptimizeRx (NASDAQ:OPRX) had its price objective reduced by equities research analysts at Barclays from $11.00 to $5.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s target price suggests a potential downside of 18.70% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. JMP Securities dropped their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research report on Thursday. Royal Bank of Canada cut their target price on OptimizeRx from $17.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Finally, B. Riley began coverage on OptimizeRx in a research report on Thursday, July 25th. They set a “buy” rating and a $18.50 target price for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.70.

OptimizeRx Stock Up 5.3 %

Shares of NASDAQ:OPRX opened at $6.15 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.07 and a quick ratio of 3.07. The stock has a market cap of $112.68 million, a price-to-earnings ratio of -6.15 and a beta of 1.32. The company has a 50 day moving average of $6.75 and a 200-day moving average of $9.07. OptimizeRx has a one year low of $5.04 and a one year high of $16.65.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its position in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the period. Quest Partners LLC raised its holdings in OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares during the period. Greenwood Capital Associates LLC lifted its stake in OptimizeRx by 8.0% in the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after buying an additional 4,999 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in OptimizeRx in the third quarter valued at approximately $810,000. Finally, Rice Hall James & Associates LLC boosted its holdings in shares of OptimizeRx by 24.0% in the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after buying an additional 119,306 shares during the period. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.